Albuminar-25

Albuminar-25 Special Precautions

human albumin

Manufacturer:

CSL Behring

Distributor:

Zuellig Pharma

Marketer:

Zuellig Pharma
Full Prescribing Info
Special Precautions
General: If dehydration is present additional fluids must accompany or follow the administration of albumin. Administration of large quantities of albumin should be supplemented with or replaced by packed red blood cells to combat the relative anemia which would follow such use. The quick response of blood pressure which may follow the rapid administration of concentrated albumin necessitates careful observation of the injured patient to detect bleeding points which failed to bleed at lower blood pressure.
Albuminar-25 should be administered with caution to patients with low cardiac reserve or with no albumin deficiency because a rapid increase in plasma volume may cause circulatory compromise (e.g. hypertension, hypotension, or pulmonary edema). In cases of hypertension, a slower rate of administration is desired - 200 mL of albumin solution may be mixed with 300 mL of 10% dextrose solution and administered at a rate of 10 grams of albumin (100 mL) per hour.
If anaphylactic or severe anaphylactoid reactions occur, discontinue infusion immediately. Infusion rates and the patient's clinical state should be monitored closely during infusion.
Information for Patient:
Some viruses, such as parvovirus B19 or hepatitis A are particularly difficult to remove or inactivate at this time. Parvovirus B19 may most seriously affect pregnant women, or immune-compromised individuals. The majority of parvovirus B19 and hepatitis A infections are acquired by environmental (community acquired) sources.
Use in Pregnancy: Pregnancy Category C: Animal reproduction studies have not been conducted with Albuminar-25. It is also not known whether Albuminar-25 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
Albuminar-25 should be given to a pregnant woman only if clearly needed.
Use in Children: No clinical studies using Albuminar-25 have been conducted in pediatric patients. Safety and effectiveness in pediatric patients have not been established. However, extensive experience in patients suggests that children respond to Albuminar-25 in the same manner as adults.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in